Corpus ID: 40706280

[Effect on animal tumors and toxicity of lycobetaine acetate (author's transl)].

  title={[Effect on animal tumors and toxicity of lycobetaine acetate (author's transl)].},
  author={S. Zhang and F. Lu and J. L. Yang and L. Wang and B. Xu},
  journal={Zhongguo yao li xue bao = Acta pharmacologica Sinica},
  volume={2 1},
  • S. Zhang, F. Lu, +2 authors B. Xu
  • Published 1981
  • Chemistry, Medicine
  • Zhongguo yao li xue bao = Acta pharmacologica Sinica
  • Lycobetaine, a derivative of lycorine, is a new type of antitumor drug. When lycobetaine acetate (AT-1840) was given ip to mice and rats inoculated with Ehrlich ascites carcinoma, ascites hepatoma, leukemia L-1210, leukemia P-388, Lewis lung cardinoma or Yoshida ascites sarcoma, the survival times of the tumor-bearing animals were prolonged significantly. Lycorine exhibited only negligible effect on the above-mentioned tumors. The acute ip LD50 of AT-1840 in mice was 72 mg/kg. In dogs iv 3 or… CONTINUE READING
    5 Citations

    Topics from this paper

    Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
    • 38
    • PDF
    Synthesis, topoisomerase-targeting activity and growth inhibition of lycobetaine analogs.
    • 24
    Chapter 1 Antitumor Alkaloids
    • 13
    Nanoemulsion loaded with lycobetaine–oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity
    • 31
    • PDF